Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Mantle Cell Lymphoma Clinical Trials

A listing of Mantle Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (12) clinical trials

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

PRIMARY OBJECTIVES: I. To evaluate the safety of brentuximab vedotin and rituximab in patients with lymphoid malignancies that are cluster of differentiation (CD) 30 positive (+) and/or Epstein-Barr virus (EBV)+, and to determine the recommended phase 2 dose (RP2D) of the combination. (Phase I) II. To evaluate the efficacy, as ...

Phase

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

The study will be conducted in two parts. Part A is a dose escalation study to determine a safe and tolerable dose of ASN002 for subjects with relapsed or refractory lymphoma, or advanced solid tumors. Part A will also characterize the pharmacokinetics and pharmacodynamics of ASN002 through blood sampling. Subjects ...

Phase

A Trial of Obinutuzumab GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients

The study will be conducted into 2 steps for respecting the optimal safety of the OASIS trial: Step A : The primary objective of step A is to evaluate the safety of the combination of GA101 + Ibrutinib at fixed doses (560 mg per day of Ibrutinib + 1000 mg ...

Phase

Ixazomib After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission

PRIMARY OBJECTIVES: I. To determine the recommended phase II dose and assess the safety of ixazomib when administered as post-transplant maintenance in mantle cell lymphoma. (Phase I) II. To assess preliminary evidence of efficacy of ixazomib when administered as post-transplant maintenance in mantle cell lymphoma. (Phase II) SECONDARY OBJECTIVES: I. ...

Phase

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.

Phase

BTK Inhibitor in B Cell Malignancies

M7583 is an investigational drug that is being evaluated for the treatment of patients with B-cell malignancies, which are cancers that form in B cells (cells that are part of the immune system). This study has been designed to assess the use of the study drug in patients with B-cell ...

Phase

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.

Phase

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant. In addition, some patients who enroll to other CD19-CAR-T cell therapy trials might ...

Phase

Study of Safety Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia

This is a phase I study of BTK inhibitor CT-1530 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia (WM). The purpose of the study is to determine the MTD/RP2D of CT-1530, and evaluate its safety and tolerability as monotherapy in ...

Phase

Safety PK PD and Antitumor Activity of SNS-062 in B Lymphoid Cancers

Phase 1b (Dose Escalation) This portion of the study will evaluate the safety and pharmacology of a range of SNS-062 dose levels administered to subjects with previously treated B-lymphoid malignancies, including: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytoid lymphoma/Waldenström's macroglobulinemia (LPL/WM), and mantle cell lymphoma (MCL). All subjects will self-administer ...

Phase